Trusted Resources: Education
Scientific literature and patient education texts
Spinal Muscular Atrophy Fact Sheet
source: National Institute of Neurological Disorders and Stroke
year: 2021
summary/abstract:What is spinal muscular atrophy?
Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons—nerve cells in the brain stem and spinal cord that control essential skeletal muscle activity such as speaking, walking, breathing, and swallowing, leading to muscle weakness and atrophy. Motor neurons control movement in the arms, legs, chest, face, throat, and tongue. When there are disruptions in the signals between motor neurons and muscles, the muscles gradually weaken, begin wasting away and develop twitching (called fasciculations).
What causes SMA?
The most common form of SMA is caused by defects in both copies of the survival motor neuron 1 gene (SMN1) on chromosome 5q. This gene produces the survival motor neuron (SMN) protein which maintains the health and normal function of motor neurons. Individuals with SMA have insufficient levels of the SMN protein, which leads to loss of motor neurons in the spinal cord, producing weakness and wasting of the skeletal muscles. This weakness is often more severe in the trunk and upper leg and arm muscles than in muscles of the hands and feet.
read more
Related Content
-
Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated With NusinersenObjective: To retrospectively evaluate t...
-
Organotypic Spinal Cord Cultures: An in Vitro 3D Model to Preliminary Screen Treatments for Spinal Muscular AtrophySpinal muscular atrophy (SMA) is a sever...
-
SMA: Considerations for Newborn Screening and Managementhttps://www.youtube.com/watch?v=FkshzHlc...
-
Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a genet...
-
Pharmacological and Clinical Profile of Onasemnogene Aveparvovec, the First Gene Therapy for Spinal Muscular Atrophy...Onasemnogene abeparvovec (Zolgensma; for...
-
New Components for Antisense Gene Therapy Show Promise in Treating Spinal Muscular AtrophySkoltech researchers and their colleague...
-
Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part ...Background: Risdiplam is an oral small m...